A genetically engineered therapeutic lectin inhibits human influenza A virus infection and sustains robust virus-specific CD8 T cell expansion
PLOS Pathogens · 07.05.2025 · 21 (5) · e1013112
DOI: 10.1371/journal.ppat.1013112 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 07.05.2025. Verfasst von Meng Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Solna, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Influenza, Human, Influenza A virus, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Swedish Heart and Lung Foundation, Vetenskapsrådet.
Abstract (Originalsprache)
Seasonal influenza continues to be a global health problem. Current existing vaccines and antivirals against influenza have limited effectiveness, and typically do not stay ahead of the viral evolutionary curve. Broad-spectrum antiviral agents that are effective therapeutically and prophylactically are much needed. We have created a promising new broad-spectrum anti-influenza agent using molecular engineering of a lectin from bananas, H84T, which is well-tolerated and protective in small animal models. However, the potency and effect of H84T on human immune cells and influenza-specific immune responses are undetermined. We found that H84T efficiently inhibited influenza A virus (IAV) replication in primary human dendritic cells (DCs) isolated from blood and tonsil, preserved DC viability and allowed acquisition and presentation of viral antigen. Excitingly, H84T-treated DCs subsequently initiated effective expansion of IAV-specific CD8 T cells. Furthermore, H84T preserved the capacity of IAV-exposed DCs to present a second non-IAV antigen and induce robust antigen-specific CD8 T cell expansion. Our data support H84T as a potent antiviral in humans as it not only effectively inhibits IAV infection, but also preserves induction of robust pathogen-specific adaptive immune responses against diverse antigens, which likely is clinically beneficial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine Solna, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, United States of America.
- Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Programs in Cellular and Molecular Biology, Immunology, and Cancer Biology, University of Michigan, Ann Arbor, Michigan, United States of America.
ORCID-Profile: Anna Smed-Sörensen
Förderung
- Swedish Research Council
- Swedish Heart and Lung Foundation
- Vetenskapsrådet
- Hjärt-Lungfonden
Zitieren
APA
Yu, M., Lin, A., Baharom, F., Li, S., Legendre, M., Covés-Datson, E., Sohlberg, E., Schlisio, S., Loré, K., Markovitz, D. M., & Smed-Sörensen, A. (2025). A genetically engineered therapeutic lectin inhibits human influenza A virus infection and sustains robust virus-specific CD8 T cell expansion. PLOS Pathogens, 21(5), e1013112. https://doi.org/10.1371/journal.ppat.1013112
Vancouver
Yu M, Lin A, Baharom F, Li S, Legendre M, Covés-Datson E, et al. A genetically engineered therapeutic lectin inhibits human influenza A virus infection and sustains robust virus-specific CD8 T cell expansion. PLOS Pathogens. 2025;21(5):e1013112. doi:10.1371/journal.ppat.1013112
BibTeX
@article{Yu2025,
author = {Yu, Meng and Lin, Ang and Baharom, Faezzah and Li, Shuijie and Legendre, Maureen and Covés-Datson, Evelyn and Sohlberg, Ebba and Schlisio, Susanne and Loré, Karin and Markovitz, David M and Smed-Sörensen, Anna},
title = {A genetically engineered therapeutic lectin inhibits human influenza A virus infection and sustains robust virus-specific CD8 T cell expansion},
journal = {PLOS Pathogens},
year = {2025},
volume = {21},
number = {5},
pages = {e1013112},
doi = {10.1371/journal.ppat.1013112}
}
EUVIMED